UroGen Pharma Ltd. (URGN)
36.83
-0.15
(-0.41%)
USD |
NASDAQ |
Oct 09, 16:00
36.83
0.00 (0.00%)
After-Hours: 20:00
UroGen Pharma Enterprise Value : 1.894B for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 1.894B |
| October 07, 2026 | 2.076B |
| October 06, 2026 | 2.111B |
| October 05, 2026 | 2.177B |
| October 02, 2026 | 2.110B |
| October 01, 2026 | 2.068B |
| September 30, 2026 | 2.072B |
| September 29, 2026 | 2.064B |
| September 28, 2026 | 2.086B |
| September 25, 2026 | 2.108B |
| September 24, 2026 | 2.102B |
| September 23, 2026 | 2.121B |
| September 22, 2026 | 2.176B |
| September 21, 2026 | 2.198B |
| September 18, 2026 | 2.200B |
| September 17, 2026 | 2.235B |
| September 16, 2026 | 2.212B |
| September 15, 2026 | 2.127B |
| September 14, 2026 | 2.171B |
| September 11, 2026 | 2.154B |
| September 10, 2026 | 2.151B |
| September 09, 2026 | 2.286B |
| September 08, 2026 | 2.228B |
| September 04, 2026 | 2.241B |
| September 03, 2026 | 2.280B |
| Date | Value |
|---|---|
| September 02, 2026 | 2.258B |
| September 01, 2026 | 2.207B |
| August 31, 2026 | 2.193B |
| August 28, 2026 | 2.219B |
| August 27, 2026 | 2.310B |
| August 26, 2026 | 2.332B |
| August 25, 2026 | 2.352B |
| August 24, 2026 | 2.343B |
| August 21, 2026 | 2.377B |
| August 20, 2026 | 2.374B |
| August 19, 2026 | 2.544B |
| August 18, 2026 | 2.478B |
| August 17, 2026 | 2.488B |
| August 14, 2026 | 2.443B |
| August 13, 2026 | 2.438B |
| August 12, 2026 | 2.481B |
| August 11, 2026 | 2.389B |
| August 10, 2026 | 2.350B |
| August 07, 2026 | 2.382B |
| August 06, 2026 | 2.315B |
| August 05, 2026 | 2.356B |
| August 04, 2026 | 2.038B |
| August 03, 2026 | 1.973B |
| July 31, 2026 | 1.956B |
| July 30, 2026 | 2.095B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 1.535B |
| MeiraGTx Holdings Plc | 958.34M |
| Insmed, Inc. | 21.52B |
| Ironwood Pharmaceuticals, Inc. | 957.22M |
| Viking Therapeutics, Inc. | 2.737B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.35M |
| Revenue (Quarterly) | 72.46M |
| Total Expenses (Quarterly) | 86.81M |
| EPS Diluted (Quarterly) | -0.2848 |
| Gross Profit Margin (Quarterly) | 90.93% |
| Profit Margin (Quarterly) | -19.81% |
| Earnings Yield | -5.41% |
| Normalized Earnings Yield | -5.414 |